Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
MENLO PARK, Calif., Jan. 18, 2017 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today its participation in the Phacilitate Cell & Gene Therapy World 2017 conference held January 17-20, 2017 in Miami, Florida. The Company will participate in the following two sessions during the conference:
Session: Vector Manufacturing: Meeting Escalating Demand for In Vivo and Ex Vivo Gene Therapy Applications
Topic: What are your options to alleviate the inefficiency of current AAV, retroviral and lentiviral vector manufacturing systems and minimize impact on cost of goods?
Panel Presenter: Mehdi Gasmi, Ph.D., Chief Technology Officer and Interim Chief Scientific Officer, Adverum Biotechnologies
Date/Time: Thursday, January 19, 2017, 2:30-3:45 p.m. ET
Session: Therapeutic Area R&D Update: CNS & Ophthalmology
Presenter: Mehdi Gasmi, Ph.D., Chief Technology Officer and Interim Chief Scientific Officer, Adverum Biotechnologies
Date/Time: Friday, January 20, 2017, 12:30 – 12:55 p.m. ET
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Jill Steier Senior Vice President The Trout Group LLC 646-378-2946 [email protected]
